Professional Documents
Culture Documents
PRESENTATION
ALKALI METALS LIMITED
HISTORY
Focused on R&D for
Started growing the
development of New
amino pyridines
Diversified Products based on
Established Sodium segments, Cyclic
into Sodium Sodium and other
in 1968 Alkoxides compounds, Fine
Derivatives. derivatives. Developed
Chemicals &
Amino Pyridines &
Tetrazoles
Derivatives
Engaged in Successfully
manufacturing completed IPO
of Alkali Sodium Sodium and listed in NSE
Sodium Azide
Metals and Amide Hydride & BSE API plant
produced under
Sodium Metal implementation
ALKALI METALS LIMITED
PROMOTERS
Main Business:
Manufacture of sodium derivatives, pyridine derivatives, fine
chemicals and custom synthesis products
ALKALI METALS LIMITED
OUR STRENGTHS
Significant expertise in Alkali Metal Derivatives
Largest manufacturer of Sodium Azides, Amides, Hydrides with
unique Technology
Strong Chemical Engineering Skills
Expertise in handling Hazardous Chemicals
Leading manufacturer of Pyridine Derivatives
All products are completely based on In-house Technology and
Engineering.
Portfolio of 341 products
Off shoring capabilities
Focus on high margin Custom Synthesis & Contract
Manufacturing
Full fledged R&D facilities for product and process development
Consistent profit generating business operations
ALKALI METALS LIMITED
OUR EXPERTISE
KEY PRODUCTS
SODIUM AZIDE
PHARMA
SODIUM HYDRIDE INTERMEDIATES
(60% OIL SUSPENSION) (SELECT
SODIUM TERTIARY BUTOXIDE THERAPIES)
• ANTI
ALKALI METAL SODIUM METHOXIDE RETROVIRALS
DERIVATIVES (POWDER / SOLUTION) • FLU VACCINE
SODIUM ETHOXIDE (TAMIFLU)
(POWDER / SOLUTION) • ANTIBIOTICS
HEXAMETHYL DISILAZANE (CIPRO)
SODIUM SALT • AGROCHEMICA
LS
POTASSIUM METAL DERIVATIVES
(POTASSIUM METHOXIDE SOLN. &
POTASSIUM TERT. BUTOXIDE)
ALKALI METALS LIMITED
KEY PRODUCTS
1H-1,2,3,4-TETRAZOLE
5-METHYL- 1H-1,2,3,4-TETRAZOLE PHARMA
TETRAZOLES 5 AMINO 1H-1,2,3,4-TETRAZOLE INTERMEDIATES
(MONOHYDRATE / ANHYDROUS) AGROCHEMICALS
5-(4-METHYL PHENYL)- 1H-1,2,3,4- AUTOMOBILE
TETRAZOLE
KEY PRODUCTS
CYCLO PENTANONE
CYCLO PENTANOL
CYCLO PENTYL MANDELIC ACID
FINE
CYCLO HEXYL MANDELIC ACID
CHEMICALS /
PHENYL PYRIDYL ACETONITRILE PHARMA
DRUG
PHENYL PYRIDYL ACETAMIDE INDUSTRY
DISCOVERY
BROMO ACETALDEHYDE
CHEMICALS
DIMETHYL ACETAL
TRI PHENYLPHOSPHINE
TRIMETHYL BORATE
SULPHA PYRIDINE
PHARMA
DISOPYRAMIDE PHARMA &
PRODUCTS &
PHENAZO PYRIDINE HCL FORMULATION
INTERMEDIATES
METHYL PHENIDATE HCL
ALKALI METALS LIMITED
CURRENT FINANCIALS
PROFIT AND LOSS ACCOUNT – Last 5 Years Rs. in Mn.
For the Year ended
Particulars 2004-05 2005-06 2006-07 2007-08 2008-09
Income
Gross Sales of products manufactured by the company 415.87 733.66 649.35 687.04 685.38
Less: Excise Duty & Sales Tax 33.89 77.36 49.25 69.36 47.56
Net Sales of products manufacturing by the company 381.98 656.30 600.10 617.68 637.82
Other Income 2.42 2.31 1.21 0.42 10.06
Increase / (Decrease) in Stock 22.48 (9.24) 38.69 35.25 (38.38)
Total 406.89 649.36 640.00 653.35 609.50
Expenditure
Raw materials Consumed 180.87 300.63 353.26 361.66 298.58
Employees cost 31.92 37.76 42.55 50.51 56.07
Power & Fuel 32.63 45.80 59.25 62.06 65.96
Other Manufacturing Cost 38.10 29.44 15.47 16.93 19.90
Research & Development Expenses 19.43 27.71 19.28 10.77 13.54
Marketing Expenses 26.73 33.12 28.49 25.71 22.58
Interest ( Financial Expenses) 11.28 17.80 20.29 17.72 15.39
Depreciation 11.28 12.81 16.87 18.17 18.50
Total 352.23 505.08 555.46 563.53 510.51
ALKALI METALS LIMITED
CURRENT FINANCIALS
PROFIT AND LOSS ACCOUNT – Last 5 Years Rs. in Mn.
For the Year ended
Particulars 2004-05 2005-06 2006-07 2007-08 2008-09
Net profit before extra ordinary Items & Tax 54.66 144.28 84.55 89.82 98.99
Extra Ordinary Item:
Loss on Sale of Investment 4.11 0.29 0.00 0.00 0.28
Current tax(Provision and payment) 2.50 9.50 6.00 10.50 11.20
Deferred Tax 1.00 1.50 2.50 0.00 (0.25)
Net profit after Tax 47.05 132.99 76.05 79.32 87.76
Amount available for appropriation 47.05 132.99 76.05 79.32 87.76
APPROPRIATION
Provision for Dividend 18.10 105.59 27.15 27.75 40.73
Provision For tax on Dividend 2.37 14.81 3.81 4.72 6.92
Transfer to General Reserve 5.00 14.00 8.00 8.00 10.00
Balance Carried over to Balance Sheet 21.58 (1.40) 37.09 38.85 30.11
ALKALI METALS LIMITED
CURRENT FINANCIALS
SUMMARY OF ASSETS AND LIABILITIES – Last 5 Years Rs. in Mn.
FY 2007-08 FY 2008-09
Japan 7%
Japan Belgium
8% 5%
India
66% Italy Italy
10% 25%
Belgium India
51%
5%
OthersGermany Others
6% 5% 12%
687 million INR 685 million INR
ALKALI METALS LIMITED
CURRENT FINANCIALS
Domestic Sales
About 50% of output is marketed to meet the needs of domestic industry.
Leading customers
Dr Reddy’s Laboratories
Ranbaxy Laboratories
Matrix Laboratories
Aurobindo
Hetero Drugs
Unimark
Sanofi Aventis
Lupin Laboratories
Glenmark Life Sciences
and Many others
ALKALI METALS LIMITED
CURRENT FINANCIALS
Export Sales
About 50% of the output is exported to leading companies in
Japan, Europe, South America and USA.
Leading customers
Mitsubishi Corporation
Innochem (Belgium)
DKSH (formerly Siber Hegner) (Japan)
Mitsui & Co Ltd (Japan)
Archmica (Italy)
Polydene (Italy)
TEVA (Israel)
and many others
ALKALI METALS LIMITED
MANUFACTURING FACILITIES
In 3 different locations, 2 locations within 8 to 34 kms from the city of Hyderabad
and 3rd one at JN Pharma city, Visakhapatnam, India
UNIT III
1
For solvents, fuel oils & other consumable, 2 (CS., SS 304, GLR, Copper, Lead Lined) Pressure (0.001 Hg-5 Kg, 25 Kg/cm
sq)
3 (Glass, MS, SS, GLR, Copper, Lead Lined) Pressure (0.001 Hg-5 Kg, 25 Kg, 50 Kg, 100 Kg/cm.sq)
ALKALI METALS LIMITED
MANUFACTURING FACILITIES
MODULE III
Proving facility to
upscale from pilot plant
to commercial scale and
establish full fledged
production
ALKALI METALS LIMITED
RESEARCH & DEVELOPMENT FACILITIES
Board of Directors
NAME Position
Board of Directors
Managing Director
Quality Environmental
Production & Research &
Management Management Systems Safety
Maintenance Developmen
Systems (QMS) (EMS)
t
ALKALI METALS LIMITED
CERTIFICATIONS
Countries of Exports
ALKALI METALS LIMITED
GLOBAL EXPOSURE
Thank You